A Phase 1 Study of S-3304 in Patients With Solid Tumors

• Status: Completed
• Trial end date: 2003-03-12
• Target enrollment: 0
• Participant gender: All

Summary

To determine the maximum tolerated dose and safety profile of S-3304 in patients with biopsy accessible cancer who have failed previous therapy or to whom no standard therapies are available. To determine the pharmacokinetic profile of S-3304 in this patient population

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shionogi
• Treatments: S 3304

Criteria

Inclusion criteria:

• Biopsy proven diagnosis of solid tumor(s) with biopsy accessible lesion(s)

• Must be able to tolerate oral medication Exclusion criteria

• Patients with other serious illnesses

• Patients who are receiving treatments